Buprenorphine Adherence Trajectories and Their Impact on Opioid Overdose and Healthcare Costs
- 11 September 2025
- journal article
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (7) , 1907-1919
Abstract
Introduction: Buprenorphine is effective for opioid use disorder (OUD), yet adherence remains suboptimal. This study aimed to identify adherence trajectories, explore their predictors, and assess their association with opioid overdose risk and healthcare costs. Methods: A retrospective cohort study was conducted using the Merative MarketScan Commercial Database, which includes a nationally representative sample of individuals with private, employer‐sponsored health insurance in the United States. We included adults (≥ 16 years) with OUD who initiated and completed at least 30 consecutive days of buprenorphine treatment between July 2017 and June 2019, with a 180‐day follow‐up. Group‐based trajectory modelling identified distinct adherence patterns. Multinomial logistic regression examined predictors of adherence trajectories. A discrete‐time survival model estimated the association between adherence and opioid overdose risk, while generalised linear models assessed healthcare costs. Sensitivity analyses, including E‐value calculations, evaluated residual confounding. Results: Among the 5107 individuals (median [Q1‐Q3] age in years: 37 [26–47]; 3185 [62.4%] male), three distinct buprenorphine adherence trajectories were identified in the follow‐up period: consistent adherence (CA, 49.5%), slow‐declining adherence (SDA, 28.0%) and rapidly‐declining adherence (RDA, 22.5%) trajectory groups. The mean (95% CI) time to buprenorphine discontinuation among all beneficiaries was 153 (151–155) days. Compared to the CA group, SDA and RDA groups had 2.74 (95% CI 2.71–2.77) and 3.81 (95% CI: 3.76–3.86) times higher opioid overdose risk and $13,670 (95% CI $7644–$19,695) and $19,431 (95% CI $13,632–$25,229) higher healthcare spending, respectively. Discussion and Conclusions: Consistent adherence to buprenorphine was associated with a lower risk of opioid overdose and reduced healthcare expenditures.Keywords
This publication has 38 references indexed in Scilit:
- Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)Contemporary Clinical Trials, 2025
- Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of FentanylJAMA Network Open, 2023
- History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorderDrug and Alcohol Dependence Reports, 2023
- Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use DisorderJAMA Psychiatry, 2022
- Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort StudyDrugs & Aging, 2022
- STROBE Reporting Guidelines for Observational StudiesJAMA Surgery, 2021
- Adherence to buprenorphine: An analysis of prescription drug monitoring program dataDrug and Alcohol Dependence, 2020
- Aggressive-Depressive Trajectories in Childhood and Their Associations with Drinking Behaviors and Problems in Adolescence and Emerging AdulthoodJournal of Youth and Adolescence, 2020
- Buprenorphine Treatment for Opioid Use Disorder: An OverviewCNS Drugs, 2019
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009